交界可切除胰腺导管腺癌新辅助治疗研究现状  

Research status of neoadjuvant therapy for borderline resectable pancreatic ductal adenocarcinoma

作　　者：陈伟武 孔月虹 张力元[1] Chen Weiwu;Kong Yuehong;Zhang Liyuan(PRaG Diagnosis and Treatment Center,Cancer Diagnosis and Treatment Center,the Second Affiliated Hospital of Soochow University,Suzhou 215000,China)

机构地区：[1]苏州大学附属第二医院肿瘤诊疗中心,布拉格治疗中心,苏州215000

出　　处：《肿瘤研究与临床》2025年第3期232-236,共5页Cancer Research and Clinic

基　　金：国家自然科学基金(82171828)。

摘　　要：胰腺癌的恶性程度高,根治性手术切除是非转移性胰腺导管腺癌的主要治疗手段,新辅助治疗能提高交界可切除胰腺导管腺癌(BR⁃PDAC)的手术切除率及延长患者生存期。近些年国内外针对胰腺癌新辅助治疗进行了大量研究,在包括放疗、化疗、免疫治疗及联合治疗方面都有相关的探索。现主要对BR⁃PDAC新辅助治疗研究现状进行综述。The malignancy of pancreatic cancer is high.Radical resection is the main treatment method for non-metastatic pancreatic ductal adenocarcinoma.Neoadjuvant therapy can improve the surgical resection rate of borderline resectable pancreatic ductal adenocarcinoma(BR-PDAC)and prolong the survival of patients.In recent years,a large number of studies have been conducted on neoadjuvant therapy for pancreatic cancer at home and abroad,including radiotherapy,chemotherapy,immunotherapy and combination therapy.This article mainly reviews the current research status of neoadjuvant therapy for BR-PDAC.

关 键 词：胰腺肿瘤 肿瘤辅助疗法 免疫疗法 

分 类 号：R735.9[医药卫生—肿瘤]